Prioritizing LDL-Cholesterol Control

Listen

0:00 / 0:00

Key Takeaways

LDL cholesterol management is vital for reducing cardiovascular disease risk and improving patient outcomes through effective lipid-lowering therapies.
Advancements in therapies, such as PCSK9 inhibitors and statins, have significantly reduced LDL levels, enhancing cardiovascular health.
Personalized treatment strategies, considering genetic predispositions and comorbidities, are essential for optimizing therapeutic outcomes.
Ongoing research explores novel therapeutic targets and strategies to further improve LDL cholesterol management and cardiovascular health.

This supplement highlights the critical role of LDL cholesterol management in reducing cardiovascular disease and improving outcomes.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

Medical personnel filing a syringe needle | Image Credit: MargJohnsonVA - stock.adobe.com.jpeg

October 22nd, 2026

Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.

Among 1332 patients in the US with genetically confirmed APOL1-mediated kidney disease, 45.7% had chronic kidney disease stage 4 or 5 at a mean age of 45.6 years. | Image credit: amazing studio - stock.adobe.com

October 22nd, 2026

Real-World AMKD Data Highlight Quick Progression, Unmet Needs

Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.

Vaccine subcutaneous injection therapy | Image credit: guerrieroale - stock.adobe.com

October 22nd, 2026

Insurance Barriers Tied to Missed Long-Acting PrEP Starts

Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.